This CME-accredited activity, Lung Cancer, is designed to improve the care of lung cancer patients by educating clinicians involved in cancer care. This activity is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care of lung cancer.
Course Accreditations
0.5 AMA PRA Category 1 Credit™ The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 1.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission. 0.5 Nursing Contact Hours Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 1.00 Contact Hours. 0.5 ABIM MOC II Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Course Summary
| Events Starts | Events Ends |
|---|---|
| 3/12/2025 | 3/12/2025 |
- Medical oncologists
- Radiation oncologists
- Surgical oncologists
- Oncology residents/fellows
- Oncology NPs/PAs
- Oncology pharmacists
- Oncology nurses
Target Audience
- Review potentially actionable molecular abnormalities in lung cancer, and the appropriate testing and treatment for actionable alteration.
- Summarize efficacy and toxicities of immune checkpoint inhibitors, targeted therapy, and other chemotherapy agents in management of management of lung cancer.
- Identify the role of perioperative systemic therapy options in curative-intent treatment of NSCLC, including the role of chemotherapy, immune checkpoint inhibitors and targeted therapy.
- Integrate emerging evidence of cutting edge developments in precision oncology into treatment paradigms for treatment of thoracic malignancies
Learning Objectives
Upon successful completion of this educational activity, participants will be able to: